Skip to search formSkip to main contentSkip to account menu

Semaxinib

Known as: Semaxanib, Sumaxanib 
A quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular… 
National Institutes of Health

Related topics

Related topics

15 relations
Angiogenesis InhibitionEndothelium, VascularInhibition of Cell ProliferationMast/Stem Cell Growth Factor Receptor Kit, human

Broader (4)

Angiogenesis InhibitorsIndolesProtein Kinase InhibitorsPyrroles

Narrower (1)

SU-5416

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The Unsettling Ambiguity of Therapeutic Extracellular Vesicles from Mesenchymal Stromal Cells
The regenerative and immunomodulatory properties of mesenchymal stromal cells (MSCs) have been long recognized, and their… 
2016
2016
Photoinduced Isomerization and Hepatoxicities of Semaxanib, Sunitinib and Related 3‐Substituted Indolin‐2‐ones
3‐Substituted indolin‐2‐ones are an important class of compounds that display a wide range of biological activities. Sunitinib is… 
2014
2014
Interferon alpha and rapamycin inhibit the growth of carcinoid and medullary thyroid cancer in vitro
Review
2013
Review
2013
Emerging VEGF-receptor inhibitors for colorectal cancer
Introduction: Targeted agents have dramatically improved and enriched the therapeutical choices for patients with metastatic… 
2013
2013
A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined with Weekly Cisplatin and Irinotecan in Patients with Advanced Solid Tumors
Background: This phase I study evaluated the safety of SU5416, a potent and selective inhibitor of the vascular endothelial… 
2013
2013
Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro.
INTRODUCTION Pheochromocytomas are benign or malignant neuroendocrine tumours. The unsatisfactory efficacy of the traditional… 
2012
2012
Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations.
2009
2009
Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma.
TO THE EDITOR: In a recent letter, Alexandrescu et al reported thoughtful data to address the occurrence of erythrocytosis after… 
2004
2004
Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
2001
2001
Semaxanib (SUGEN).
  • K. Sakamoto
  • IDrugs : the investigational drugs journal
  • 2001
  • Corpus ID: 20876991
SUGEN (owned by Pharmacia) is developing semaxanib (SU-5416), the lead in a series of small molecule inhibitors of the flk-1… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)